T1	Participants 63 99	postoperative rectal cancer patients
T2	Participants 319 425	postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)
T3	Participants 435 563	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin
